未分化自身炎症性疾病的下一代测序 panel 识别秋水仙碱应答的复发性发热患者
本研究评估面向临床的下一代测序(NGS)panel 在未分化或未定义系统性自身炎症性疾病(uSAID)患者中的应用。基因阴性复发性发热患者以胃肠道、皮肤和关节受累为主,对按需激素(94%)和秋水仙碱(应答率 78%)有应答。
要点
- NGS panel 在 uSAID 中分子诊断率低,但可为部分患者提供最终诊断。
- 基因阴性复发性发热患者常见胃肠道、皮肤和关节受累。
- 该亚组对按需激素和秋水仙碱应答率较高。
核心结论
- 基于 NGS 的方法虽分子诊断率低,仍能为部分 uSAID 患者提供最终诊断并具成本效益。
- NGS 可识别对按需激素和秋水仙碱有应答的基因阴性复发性发热患者亚组。
研究设计与样本
- 研究设计 NGS panel,涵盖 41 个基因,分为 7 个子 panel。
主要发现
- 共发现 100 个基因变异(人均 2 个,范围 0-6),其中四分之一涉及疑似基因。
- 2 例患者检出具有明确诊断影响的突变。
- 基因阴性复发性发热患者以胃肠道、皮肤和关节受累为主。
关键数值与推荐
- 基因阴性复发性发热患者对按需激素的应答率为 94%。
- 基因阴性复发性发热患者对秋水仙碱的应答率为 78%。
临床怎么用
- 对临床表型符合 uSAID 的患者可行 NGS panel 检测以辅助分子诊断。
- 对基因阴性的复发性发热患者,可考虑按需激素及秋水仙碱治疗并评估应答。
局限性
- 分子诊断率低,仅 2 例检出具有明确诊断影响的突变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The number of innate immune system disorders classified as systemic autoinflammatory diseases (SAID) has increased in recent years. More than 70% of patients with clinical manifestations of SAID did not receive a molecular diagnosis, thus being classed as so-called undifferentiated or undefined SAID (uSAID). The aim of the present study was to evaluate a next-generation sequencing (NGS)-based clinically oriented protocol in patients with uSAID. METHODS: We designed a NGS panel that included 41 genes clustered in seven subpanels. Patients with uSAID were classified into different groups according to their clinical features and sequenced for the coding portions of the 41 genes. RESULTS: Fifty patients were enrolled in the study. Thirty-four patients (72%) displayed recurrent fevers not consistent with a PFAPA phenotype. Sixteen patients displayed a chronic inflammatory disease course. A total of 100 gene variants were found (mean 2 per patient; range 0-6), a quarter of which affected suspected genes. Mutations with a definitive diagnostic impact were detected in two patients. Patients with genetically negative recurrent fevers displayed a prevalent gastrointestinal, skin and articular involvement. Patients responded to steroids on demands (94%) and colchicine, with a response rate of 78%. CONCLUSION: Even with a low molecular diagnostic rate, a NGS-based approach is able to provide a final diagnosis in a proportion of uSAID patients with evident cost-effectiveness. It also allows the identification of a subgroup of genetically negative patients with recurrent fever responding to steroid on demand and colchicine.
引用
- Papa R, Rusmini M, Volpi S, et al. Next generation sequencing panel in undifferentiated autoinflammatory diseases identifies patients with colchicine-responder recurrent fevers. Rheumatology (Oxford). 2020. PMID: 31325311. doi:10.1093/rheumatology/kez270
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。